We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Docandu is an innovative digital health platform designed both for patients & doctors, making digital healthcare accessible from anywhere. Docandu aims to be a key tech health service provider, starting from Greece, improving the existing national and private health care services. The global digital health market is estimated to be worth $536 Billion by 2025. To date, they have developed two separate apps for doctors and patients. They have also received an angel investment of 100,000 Euros and sponsorship of $25,000 from Microsoft. The company has initiated early-stage relationships with a couple of Greek public and private health entities. With the proceeds, they will execute their go-to-market strategy and make global health ID a reality, by expanding its affiliate network of doctors, health providers and public health systems.

Pitch Rated

82%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £70,900
Revolupin Lupin flakes are the tasty, plant-based, certified vegan, pre-biotic, gluten-free, high-fibre and low-carb superfood. It is ready to make full use of the huge increase of 27% growth (2013-2015) in sports nutrition sales and the new market opportunity for being a 100% natural plant-based protein. Revolupin had won the Women’s Health Best Superfood Award in 2018. It has also secured a successful distribution via Wholefoods Wholesale and The Health Store. Revolupin has also launched a new online store on its official website. With its proceeds, the company will increase its production, sales and generate brand awareness. Revolupin will support retail, build the distribution network, and develop new recipes of ready-to-use food items and products.
days to go: Expired investment: £77,110
GIBIE combines ancient Indian dying methods with modern weaving technologies to produce sustainable and luxurious homewares. The company argues that the textile industry uses an astonishing 9 trillion gallons of water annually, as well as, releases harmful gases and chemicals in the air and water. GIBIE aims to change this scenario by bringing forth sustainable linen that has superior qualities to chemically enhanced and dyed linen. It has come out with an industrial-scale production proposal of its linen. The company is a PETA-approved vegan brand and a member of the Color Ashram Foundation that promotes the usage of herbal dyes around the world. GIBIE will use the investment to launch its essential sales programs, boost marketing initiatives and scale production.

Pitch Rated

57%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £158,571
Bazar is the UK’s first dedicated ethical marketplace and lifestyle application. The company intends to disrupt the ~£32.8 billion UK consumer marketplace by creating a platform where eco-friendly businesses can thrive, and consumers can trust brand values. It brings curated ethical and eco-friendly brands, artisans, and items under one portal. BAZAR soft-launched its application with 35 sellers and 650 products in the COVID-19 lockdown which doubled showing positive seller demand. The app saw over 1800 downloads with early sales. The company has a social media presence with over 1500+ Instagram followers. It intends to enter the US market in 2022, followed by Europe. Bazar will use the investment to continue to develop its technology to help sellers grow their business and give buyers an intuitive shopping experience on the app. 

Pitch Rated

49%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £208,368
DNApal is a personalised diet, health and fitness app that combines DNA infomation with other factors like age, weight, diet, family history and health goals. Two of the largest consumer DNA companies, 23andMe and Ancestry.com, have tested over 18m people. DNApal is capable of interpreting DNA results from these companies to provide precise recommendations on how to improve diet, hormone balance, weight loss, sleep, fitness & more. The company also won the best pitch at VentureFest 2019 at Oxford Brookes University. DNApal is aiming to launch MVP in January 2020 (iOS). The company is also aiming to recommend further testing and specific supplements where necessary and offer 1:1 consultations with a specialist. With the fund raised, DNApal plans to develop the full scope of the app, weekly goals, content challenges to keep users committed.

Pitch Rated

70%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £49,990
PlusGuidance is an online counselling/therapy platform that gives people immediate access to counselling. It provides secure video, voice, IM and email sessions directly through the site, and booking in-person sessions too. Our Mission - Immediate access to counselling for everyone. Business Model - Software-as-a-Service for counsellors, who pay a monthly fee to use secure online sessions, practice management tools to manage their clients, and a public web profile in our directory.
days to go: Expired investment: £64,987
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph